Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness

doi:10.3748/wjg.v25.i34.5097

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11885)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

1072

WORD

298

HTML

6719

Tables (1-2)

214

Sum=8303

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

823

Download

678

Sum=1501

Publishing Process of This Article

Item

Count

Browse

816

Download

1265

Sum=2081

Sep 14, 2019 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (50)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Sep 14, 2019; 25(34): 5097-5104
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5097

Table 2 Randomized controlled trials comparing vonoprazan vs proton pump inhibitors for Helicobacter pylori eradication regimens

Study	Protocol in vonoprazan group	Protocol in PPI group	Eradication rate in vonoprazan group	Eradication rate in PPI group
Murakami et al[53], 2016	Vonoprazan 20 mg bid	LAN 30 mg AMO 750 mg bid	299/329 (90.9%)	241/321 (75.1%)
	AMO 750 mg bid	CLA 400 mg bid
	CLA 400 mg bid
Maruyama et al[54], 2017	Vonoprazan 20 mg bid	LAN 30 mg or RAB 20 mg bid	69/72 (95.8%)	48/69 (69.6%)
	AMO 750 mg bid	AMO 750 mg bid
	CLA 400 mg bid	CLA 400 mg bid
Sue et al[55], 2018	Vonoprazan 20 mg bid	LAN 30 mg or RAB 10 mg or ESO 20 mg bid	48/55 (87.3%)	39/51 (76.5%)
	AMO 750 mg bid	AMO 750 mg bid
	CLA 400 mg bid	CLA 400 mg bid

All percentages are expressed as intention to treat. AMO: Amoxicillin; CLA: Clarithromycin; ESO: Esomeprazole; LAN: Lansoprazole; RAB: Rabeprazole; PPI: Proton pump inhibitors.

Citation: Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol 2019; 25(34): 5097-5104
URL: https://www.wjgnet.com/1007-9327/full/v25/i34/5097.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i34.5097